Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of approach to endometrial cancer survivors

Linda R Duska, MD
Section Editor
Larissa Nekhlyudov, MD, MPH
Deputy Editors
Sadhna R Vora, MD
Sandy J Falk, MD, FACOG


Endometrial cancer is the most common of the gynecologic cancers. Almost 3 percent of women born in the United States (US) in 2013 will be diagnosed with uterine cancer during their lifetime. This represents an increase in the incidence of uterine cancer in the US over the years 2006 to 2010 [1], which is likely due to women living longer and the increasing rates of obesity in the US.

Fortunately, most women with endometrial cancer will survive their initial diagnosis, making this the largest group of survivors who had a gynecologic malignancy [2]. For example, in the US there are over 624,000 survivors with a history of uterine cancer as of 2014, which is estimated to climb to over 750,000 survivors by 2024 [3]. Unfortunately, there is a lack of clear evidence for what constitutes best practices in caring for patients with a history of endometrial cancer. Recommendations for posttreatment surveillance after primary therapy of endometrial cancer will be reviewed here.

For purposes of this discussion, we will address survivorship as it pertains to patients who have completed initial treatment for endometrial cancer and who are without evidence of disease.

The treatment of patients with endometrial cancer is discussed separately.

(See "Overview of endometrial carcinoma".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 8, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. SEER Stat Fact Sheets: Corpus and Uterus, NOS. seer.cancer.gov/statfacts/html.corp.html (Accessed on September 02, 2013).
  2. Estimated number of cancer survivors in the United States as of January 1, 2012 by cancer site and years from diagnosis. http://cancercontrol.cancer.gov/ocs/prevalence/prevalence.html#survivor (Accessed on December 10, 2013).
  3. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014; 64:252.
  4. Salani R, Backes FJ, Fung MF, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011; 204:466.
  5. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).
  6. Novetsky AP, Kuroki LM, Massad LS, et al. The utility and management of vaginal cytology after treatment for endometrial cancer. Obstet Gynecol 2013; 121:129.
  7. Bristow RE, Purinton SC, Santillan A, et al. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 2006; 103:709.
  8. Kadkhodayan S, Shahriari S, Treglia G, et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol 2013; 128:397.
  9. Fung-Kee-Fung M, Dodge J, Elit L, et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006; 101:520.
  10. Ben Arie A, Lavie O, Gdalevich M, et al. Temporal pattern of recurrence of stage I endometrial cancer in relation to histological risk factors. Eur J Surg Oncol 2012; 38:166.
  11. Tjalma WA, van Dam PA, Makar AP, Cruickshank DJ. The clinical value and the cost-effectiveness of follow-up in endometrial cancer patients. Int J Gynecol Cancer 2004; 14:931.
  12. Sartori E, Pasinetti B, Chiudinelli F, et al. Surveillance procedures for patients treated for endometrial cancer: a review of the literature. Int J Gynecol Cancer 2010; 20:985.
  13. Menczer J. Endometrial carcinoma. Is routine intensive periodic follow-up of value? Eur J Gynaecol Oncol 2000; 21:461.
  14. Otsuka I, Uno M, Wakabayashi A, et al. Predictive factors for prolonged survival in recurrent endometrial carcinoma: Implications for follow-up protocol. Gynecol Oncol 2010; 119:506.
  15. Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89:201.
  16. Miller DS, Filiaci G, Mannel R, et al. Randomized Phase III Noninferiority Trial of First Line Chemotherapy for Metastatic or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. LBA2. Presented at the 2012 Society of Gynecologic Oncology Annual Meeting, Austin, TX.
  17. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006; 24:1633.
  18. von Gruenigen VE, Gil KM, Frasure HE, et al. The impact of obesity and age on quality of life in gynecologic surgery. Am J Obstet Gynecol 2005; 193:1369.
  19. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002; 11:1531.
  20. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009; 114:121.
  21. Soliman PT, Bassett RL Jr, Wilson EB, et al. Limited public knowledge of obesity and endometrial cancer risk: what women know. Obstet Gynecol 2008; 112:835.
  22. von Gruenigen VE, Tian C, Frasure H, et al. Treatment effects, disease recurrence, and survival in obese women with early endometrial carcinoma : a Gynecologic Oncology Group study. Cancer 2006; 107:2786.
  23. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.
  24. Abu-Abid S, Szold A, Klausner J. Obesity and cancer. J Med 2002; 33:73.
  25. Courneya KS, Karvinen KH, Campbell KL, et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol 2005; 97:422.
  26. von Gruenigen VE, Waggoner SE, Frasure HE, et al. Lifestyle challenges in endometrial cancer survivorship. Obstet Gynecol 2011; 117:93.
  27. Basen-Engquist K, Scruggs S, Jhingran A, et al. Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol 2009; 200:288.e1.
  28. Fader AN, Frasure HE, Gil KM, et al. Quality of life in endometrial cancer survivors: what does obesity have to do with it? Obstet Gynecol Int 2011; 2011:308609.
  29. Oldenburg CS, Boll D, Nicolaije KA, et al. The relationship of body mass index with quality of life among endometrial cancer survivors: a study from the population-based PROFILES registry. Gynecol Oncol 2013; 129:216.
  30. Demark-Wahnefried W, Peterson B, McBride C, et al. Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer 2000; 88:674.
  31. Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005; 23:5814.
  32. Jernigan AM, Maurer KA, Cooper K, et al. Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study. Am J Obstet Gynecol 2015; 213:350.e1.
  33. Onujiogu N, Johnson T, Seo S, et al. Survivors of endometrial cancer: who is at risk for sexual dysfunction? Gynecol Oncol 2011; 123:356.
  34. Chadha M, Nanavati PJ, Liu P, et al. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 1999; 75:103.
  35. Eltabbakh GH, Piver MS, Hempling RE, Shin KH. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys 1997; 38:373.
  36. Pearcey RG, Petereit DG. Post-operative high dose rate brachytherapy in patients with low to intermediate risk endometrial cancer. Radiother Oncol 2000; 56:17.
  37. Weiss E, Hirnle P, Arnold-Bofinger H, et al. Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: patterns of relapse and side effects following low-dose therapy. Gynecol Oncol 1998; 71:72.
  38. Nout RA, Putter H, Jürgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27:3547.
  39. White ID. The assessment and management of sexual difficulties after treatment of cervical and endometrial malignancies. Clin Oncol (R Coll Radiol) 2008; 20:488.
  40. Falk SJ, Dizon DS. Sexual dysfunction in women with cancer. Fertil Steril 2013; 100:916.
  41. DeSimone M, Spriggs E, Gass JS, et al. Sexual dysfunction in female cancer survivors. Am J Clin Oncol 2014; 37:101.
  42. Krychman ML, Pereira L, Carter J, Amsterdam A. Sexual oncology: sexual health issues in women with cancer. Oncology 2006; 71:18.
  43. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 1984; 64:417.
  44. Whitaker GK, Lee RB, Benson WL. Carcinoma of the endometrium in young women. Mil Med 1986; 151:25.
  45. Hitchcock CL, Prior JC. Oral micronized progesterone for vasomotor symptoms--a placebo-controlled randomized trial in healthy postmenopausal women. Menopause 2012; 19:886.
  46. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009; 27:2831.
  47. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295:2057.
  48. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology 2004; 13:769.
  49. http://seer.cancer.gov/statfacts/html/corp.html (Accessed on December 14, 2011).
  50. Biglia N, Gadducci A, Ponzone R, et al. Hormone replacement therapy in cancer survivors. Maturitas 2004; 48:333.
  51. Ibeanu O, Modesitt SC, Ducie J, et al. Hormone replacement therapy in gynecologic cancer survivors: why not? Gynecol Oncol 2011; 122:447.
  52. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996; 175:1195.
  53. Suriano KA, McHale M, McLaren CE, et al. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 2001; 97:555.
  54. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986; 67:326.
  55. Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990; 36:189.
  56. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24:587.
  57. Committee on Gynecologic Practice. ACOG committee opinion. Hormone replacement therapy in women treated for endometrial cancer. Number 234, May 2000 (replaces number 126, August 1993). Int J Gynaecol Obstet 2001; 73:283.
  58. Ryan M, Stainton MC, Jaconelli C, et al. The experience of lower limb lymphedema for women after treatment for gynecologic cancer. Oncol Nurs Forum 2003; 30:417.
  59. Nunns D, Williamson K, Swaney L, Davy M. The morbidity of surgery and adjuvant radiotherapy in the management of endometrial carcinoma. Int J Gynecol Cancer 2000; 10:233.
  60. Abu-Rustum NR, Alektiar K, Iasonos A, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 2006; 103:714.
  61. van de Poll-Franse LV, Pijnenborg JM, Boll D, et al. Health related quality of life and symptoms after pelvic lymphadenectomy or radiotherapy vs. no adjuvant regional treatment in early-stage endometrial carcinoma: a large population-based study. Gynecol Oncol 2012; 127:153.
  62. May K, Bryant A, Dickinson HO, et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2010; :CD007585.
  63. Angioli R, Plotti F, Cafà EV, et al. Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy. Eur J Obstet Gynecol Reprod Biol 2013; 170:539.
  64. Frid M, Strang P, Friedrichsen MJ, Johansson K. Lower limb lymphedema: experiences and perceptions of cancer patients in the late palliative stage. J Palliat Care 2006; 22:5.
  65. Kim SJ, Park YD. Effects of complex decongestive physiotherapy on the oedema and the quality of life of lower unilateral lymphoedema following treatment for gynecological cancer. Eur J Cancer Care (Engl) 2008; 17:463.
  66. Langbecker D, Hayes SC, Newman B, Janda M. Treatment for upper-limb and lower-limb lymphedema by professionals specializing in lymphedema care. Eur J Cancer Care (Engl) 2008; 17:557.
  67. Williams AF, Franks PJ, Moffatt CJ. Lymphoedema: estimating the size of the problem. Palliat Med 2005; 19:300.
  68. Kim CH, Khoury-Collado F, Barber EL, et al. Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol 2013; 131:714.
  69. Abu-Rustum NR. The increasing credibility of sentinel lymph node mapping in endometrial cancer. Ann Surg Oncol 2013; 20:353.
  70. Courtney-Brooks M, Scalici JM, Tellawi AR, et al. Para-aortic lymph node dissection for women with endometrial adenocarcinoma and intermediate- to high-risk tumors: does it improve survival? Int J Gynecol Cancer 2014; 24:91.
  71. Andreyev HJ. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol) 2007; 19:790.
  72. Klee M, Machin D. Health-related quality of life of patients with endometrial cancer who are disease-free following external irradiation. Acta Oncol 2001; 40:816.
  73. Bye A, Tropé C, Loge JH, et al. Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy--evaluation of long-term effects of diagnosis and treatment. Acta Oncol 2000; 39:173.
  74. Li C, Samsioe G, Iosif C. Quality of life in endometrial cancer survivors. Maturitas 1999; 31:227.
  75. Vistad I, Cvancarova M, Fosså SD, Kristensen GB. Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients? Int J Radiat Oncol Biol Phys 2008; 71:1335.
  76. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000; 355:1404.
  77. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:744.
  78. Le T, Menard C, Samant R, et al. Longitudinal assessments of quality of life in endometrial cancer patients: effect of surgical approach and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2009; 75:795.
  79. Ko EM, Funk MJ, Clark LH, Brewster WR. Did GOG99 and PORTEC1 change clinical practice in the United States? Gynecol Oncol 2013; 129:12.
  80. Poorvu PD, Sadow CA, Townamchai K, et al. Duodenal and other gastrointestinal toxicity in cervical and endometrial cancer treated with extended-field intensity modulated radiation therapy to paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2013; 85:1262.
  81. Lind H, Waldenström AC, Dunberger G, et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. Br J Cancer 2011; 105:737.
  82. Bruegl AS, Djordjevic B, Urbauer DL, et al. Utility of MLH1 methylation analysis in the clinical evaluation of Lynch Syndrome in women with endometrial cancer. Curr Pharm Des 2014; 20:1655.
  83. Kwon JS, Elit L, Saskin R, et al. Secondary cancer prevention during follow-up for endometrial cancer. Obstet Gynecol 2009; 113:790.